Biomarker analyses, including the MET expression in these phase III trials, will clarify the role of MET expression by IHC, and further research on other predictive markers of HGF/MET inhibitors, including the serum level of HGF, are required in advanced GC patients. This evidence concerns the gene MET and gastric cancer.